Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TRML
- Price
- 47.98
- Stock movement up
- +- (%)
- Company name
- Tourmaline Bio Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.23B
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 80.44%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-10-30
DIVIDENDS
TRML does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -4.25 |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 31.42M |
| Net receivables | 0.00 |
| Total current assets | 249.10M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 174.00K |
| Total assets | 269.30M |
| Accounts payable | 3.17M |
| Short/Current long term debt | 145.00K |
| Total current liabilities | 10.10M |
| Total liabilities | 10.10M |
| Shareholder's equity | 0.00 |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 47.98 |
| Daily high | 47.98 |
| Daily low | 47.98 |
| Daily Volume | 0K |
| All-time high | 186.10 |
| 1y analyst estimate | 48.00 |
| Beta | 1.58 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | 20 Oct 2023 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| TRML | S&P500 | |
| Current price drop from All-time high | -74.22% | - |
| Highest price drop | -93.50% | -19.00% |
| Date of highest drop | 10 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -87.43% | -2.76% |
| Avg time to new high | - | 5 days |
| Max time to new high | 265 days | 89 days |
COMPANY DETAILS
Marketcap
1.23B
Marketcap category
Small-cap
Description
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Tourmaline Bio, Inc. operates as a subsidiary of Novartis AG.
Employees
76
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner